Karen Drexler - ResMed Independent Director
| RMD Stock | USD 243.60 2.05 0.85% |
Director
Ms. Karen Drexler is Independent Director of the Company since November 2017. She is a member of our compensation committee. Ms. Drexler is currently president, chief executive officer and a board member of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for pointofcare medical testing. She was on its board since 2014, and became CEO in 2016. Ms. Drexler also serves on the board of directors of AP360, a forprofit subsidiary of Medicines360, a womens health company. From 2011 to 2017, Ms. Drexler served as chairman of the board of directors of Hygieia, Inc., a private digital insulin therapy company. She remains involved as an advisor to the CEO. Ms. Drexler also acts as a senior strategic advisor for several other early stage companies and is on the board of directors for the Keller Center for Innovation in Engineering Education at Princeton University. Ms. Drexler has served on numerous private company boards in the past in the fields of diagnostics, medical devices and digital health. Ms. Drexler is an active mentor and advisor with Astia, a global nonprofit that supports high potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders. Ms. Drexler is also a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science Council for Springboard, an accelerator for womenled technologyoriented companies. Through her work with Astia, Springboard and StartX, Ms. Drexler interacts with many promising young medtech companies. Ms. Drexler was the president and chief executive officer of Amira Medical Inc., a private company focused on minimally invasive glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. From 1984 to 1995, she held various positions in marketing, sales, manufacturing, business development, and research and development at LifeScan. since 2017.
| Age | 60 |
| Tenure | 7 years |
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
ResMed Management Efficiency
The company has Return on Asset of 0.1327 % which means that on every $100 spent on assets, it made $0.1327 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2357 %, implying that it generated $0.2357 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.30, whereas Return On Capital Employed is forecasted to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 482.8 M, whereas Net Tangible Assets are forecasted to decline to about 632.7 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Friel | West Pharmaceutical Services | 65 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| James Gavin | Baxter International | 73 | |
| Timothy Ring | Becton Dickinson and | 63 | |
| Mark Buthman | West Pharmaceutical Services | 60 | |
| Thomas Hofmann | West Pharmaceutical Services | 68 | |
| Claire Pomeroy | Becton Dickinson and | 65 | |
| Douglas Michels | West Pharmaceutical Services | 63 | |
| Patricia Morrison | Baxter International | 61 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
| Arthur MD | Alcon AG | 62 | |
| Jeffrey Henderson | Becton Dickinson and | 56 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| Michael Mahoney | Baxter International | 56 | |
| Cathy Smith | Baxter International | 57 | |
| Peter Hellman | Baxter International | 71 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| Jody Lindell | The Cooper Companies, | 69 | |
| George Babich | Teleflex Incorporated | 69 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Secretary | ||
| Vered Keisar, Chief Officer | ||
| Carlos MD, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Michael Fliss, Chief Officer | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Constance Bienfait, Director Relations | ||
| Hemanth Reddy, Chief Officer | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Dawn Haake, Chief Officer | ||
| Justin Leong, President – Asia and Latin America | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer | ||
| Alastair Robertson, Chief Officer | ||
| Todd Friedman, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 35.88 B | ||||
| Shares Outstanding | 146.8 M | ||||
| Shares Owned By Insiders | 0.77 % | ||||
| Shares Owned By Institutions | 61.20 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 73.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.416 | Dividend Share 1.97 | Earnings Share 7.55 | Revenue Per Share 32.711 | Quarterly Revenue Growth 0.111 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.